Palatin Technologies doses first subject in Phase II obesity treatment trial [Yahoo! Finance]
Palatin Technologies, Inc. (PTN)
NASDAQ:AMEX Investor Relations:
palatin.com/investors/overview
Company Research
Source: Yahoo! Finance
Bremelanotide is a melanocortin 4 receptor (MC4R) while tirzepatide is a GLP-1/GIP receptor agonist. Dubbed BMT-801, the randomised, double-blind, placebo-controlled trial is designed to assess the safety, tolerability, and efficacy of this combination therapy. The trial aims to enrol up to 60 subjects across four US sites. Demonstrating the safety and enhanced efficacy in reducing body weight through the co-administration of bremelanotide and tirzepatide is the trial's primary endpoint. The study will initially treat subjects with tirzepatide alone for four weeks, confirm their eligibility, and then randomise them to one of four treatment regimens, the company noted. Throughout the trial, various assessments will be conducted to evaluate the safety and efficacy of bremelanotide, both as monotherapy and in combination with GLP-1/GIP therapy. Full subject enrolment in the BMT-801 study is anticipated by the third quarter of this year, with topline data read out in the firs
Show less
Read more
Impact Snapshot
Event Time:
PTN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTN alerts
High impacting Palatin Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
PTN
News
- Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... [Yahoo! Finance]Yahoo! Finance
- Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results [Yahoo! Finance]Yahoo! Finance
- Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial ResultsPR Newswire
- Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024PR Newswire
- Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024PR Newswire
PTN
Earnings
- 11/14/24 - Beat
PTN
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 10/30/24 - Form 424B3
- PTN's page on the SEC website